Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

What you say makes sense, else how would generics be launched at-risk?

That’s correct—“at risk” generic launches (which are more common than some people realize,) require final rather than tentative FDA approval.

On the other hand, TEVA’s press release says they believe the [Distrcit Court] ruling "should" prevent FDA approval…

Teva’s PR uses the word should rather than the word will because Teva is stating an opinion rather than a matter of Hatch-Waxman law.